Biologic switching in psoriatic arthritis: Insights from real-world data and key risk factors

This publication has 27 references indexed in Scilit:

• Cycling versus swapping strategies with TNF-α inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice
  Scientific Reports, 2024
• Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis
  The Lancet Rheumatology, 2023
• Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials
  Immunologic Research, 2023
• Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study
  Clinical Rheumatology, 2021
• Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
  The Lancet, 2020
• Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors
  Current Medical Research and Opinion, 2019
• 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
  Arthritis & Rheumatology, 2018
• Switching biologics in the treatment of psoriatic arthritis
  Seminars in Arthritis and Rheumatism, 2017
• Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis
  Clinical Rheumatology, 2016
• Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry
  Arthritis & Rheumatism, 2013